A randomized, double-blind, phase iii, non-inferiority clinical trial comparing the efficacy and safety of ta4415v (a proposed trastuzumab biosimilar) and herceptin (trastuzumab reference product) in her2-positive early-stage breast cancer patients

HIGHLIGHTS

• who: Reza Safaei Nodehi from the treated in the neoadjuvant setting in IranTehran University of Medical Sciences, Tehran, Iran have published the research work: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients, in the Journal: (JOURNAL)
• what: Background: This study compared efficacy and safety of TA4415V with in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early-stage breast cancer treated in the neoadjuvant setting in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.